(PharmaNewsWire.Com, April 12, 2019 ) The interventional cardiology devices market is expected to reach USD 20.85 Billion by 2022 from USD 13.50 Billion in 2016 at a CAGR of 7.5%. The base year for this study is 2016 and the forecast period is 2017–2022.
The key players in the interventional cardiology devices market include Medtronic (US), Boston Scientific (US), Abbott Laboratories (US), Terumo (Japan), Cordis (US), B. Braun (Germany), C.R. Bard (US), Biosensors (Singapore), and BIOTRONIK (Germany).
Market growth is primarily driven by the growing incidence of CVD and technological advancements in interventional cardiology devices.
The global interventional cardiology devices market is segmented based on type and region
Major industry players launched innovative products to maintain and improve their position in the interventional cardiology devices market. Medtronic (US), Boston Scientific (US), Abbott Laboratories (US), Terumo (Japan), Cordis (US), B. Braun (Germany), C.R. Bard (US), Biosensors (Singapore), and BIOTRONIK (Germany) have been identified as key players in this market.
These companies have broad product portfolios with comprehensive features and have also launched innovative products. These leaders also have products for all end users in this market, strong geographical presence, and a focus on continuous product innovation.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
